BOSTON (Reuters) - Wall Street's savviest investors are picking sides on Bill Ackman's new bet on Valeant Pharmaceuticals International Inc , with BlueMountain Capital and T. Rowe Price adding money, while Viking Global Investors and Jana Partners cut stakes.
more: http://wp.me/p55gzU-9OE. #BusinessNews
Keine Kommentare:
Kommentar veröffentlichen